Pharmacists’ Expanding Role in Hematologic Malignancies

Here’s a breakdown of the key information from‍ the provided text, focusing on MMR vaccination in⁣ patients wiht ‍multiple myeloma‌ (MM) receiving daratumumab after autologous stem ​cell‌ transplantation (ASCT):

The Problem:

* Patients⁣ with MM undergoing daratumumab treatment⁢ (and often after ASCT) are generally contraindicated for live-attenuated vaccines like MMR due to the risk of disseminated infection.
* However, with increasing use of daratumumab and a recent measles outbreak (over 1800 cases in ⁢2025), understanding the risks of MMR vaccination in these patients is crucial.
* Vaccine hesitancy adds​ to the need for accurate information.

The Study:

* A retrospective study was conducted by James Davis and colleagues ⁣at 5 US academic medical centers.
* ​ 41 patients with MM​ receiving daratumumab after ASCT were analyzed.
* MMR vaccination was administered at the ⁢oncologist’s discretion.
*‍ Limitation: Vaccine titer measurements were not routinely taken.
* Researchers monitored for adverse events (AEs) like infections,⁣ rash, and malaise.

Key Findings:

* ‍the first ​MMR dose⁢ was given at a median of 22 daratumumab cycles (616 days post-treatment) and ‍the median ⁤time from ASCT to ⁤MMR vaccination was 768 days.
* 4 patients received a second MMR dose.
* common AEs were acute sinusitis (5%) and COVID-19 infection (5%), occurring⁢ about 8 days after vaccination.
* Importantly, no patients developed active MMR infection, ​and there were no hospitalizations or deaths.

Conclusion:

* The study suggests that MMR vaccination may be safe in immunocompromised patients with MM‍ receiving daratumumab after ASCT, despite the current contraindications.
* The sample size was⁣ limited, so further​ research is needed.
* ⁤ Pharmacists can play a vital role in advocating for vaccination,administering‌ vaccines,and counseling patients.
* ‌ Extensive monitoring is essential for patients receiving live-attenuated vaccines while on daratumumab.